<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879654</url>
  </required_header>
  <id_info>
    <org_study_id>SNMM-SA-V1</org_study_id>
    <nct_id>NCT04879654</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery</brief_title>
  <acronym>SNMM</acronym>
  <official_title>Phase II, Single-arm, Prospective Clinical Study of Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of Sinonasal Malignant Mucosal Melanoma（SNMM） After Endoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined&#xD;
      with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma&#xD;
      after endoscopic surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first treatment until the date of death from any cause,through study completion,up to 3 years.]</time_frame>
    <description>3 year Overall Survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first，through study completion,up to 3 years.</time_frame>
    <description>the date of first treatment to the first recording of disease progression or death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Local progression free survival</measure>
    <time_frame>From date of first treatment to local failure or date of death from any cause,through study completion,up to 3 years.</time_frame>
    <description>the date of first treatment to local failure or death</description>
  </other_outcome>
  <other_outcome>
    <measure>Regional progression free survival</measure>
    <time_frame>From date of first treatment to regional failure or date of death from any cause, through study completion,up to 3 years.</time_frame>
    <description>the date of first treatment to regional failure or death</description>
  </other_outcome>
  <other_outcome>
    <measure>Distant metastasis free survival</measure>
    <time_frame>From date of first treatment to distant metastasis or date of death from any cause, through study completion,up to 3 years.]</time_frame>
    <description>the date of first treatment to distant metastasis or death</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicities</measure>
    <time_frame>From date of first treatment through study completion,up to 3 years.</time_frame>
    <description>Using CTCAE Version5.0 to evaluate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Sinonasal Melanoma</condition>
  <arm_group>
    <arm_group_label>endonasal endoscopic surgery with adjuvant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endonasal endoscopic surgery followed by Toripalimab,radiotherapy and/or chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic surgery</intervention_name>
    <description>endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy</description>
    <arm_group_label>endonasal endoscopic surgery with adjuvant therapy</arm_group_label>
    <other_name>radiotherapy</other_name>
    <other_name>chemotherapy</other_name>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Pathologically diagnosed as sinonasal malignant mucosal melanoma, locally resectable and&#xD;
        no contraindication for surgery or radiation. 2.T3 and T4. 3.Age ≥18 year-old 4.No distant&#xD;
        metastasis 5.No head and neck radiation and systemic anti-tumor therapy performed in the&#xD;
        past 5 years. 6.The performance status of the Eastern Cooperative Oncology Group(ECOG) is&#xD;
        0-2 points and surgery after general anesthesia and postoperative radiation could be&#xD;
        tolerated. 7.Accepted organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients who refused to sign informed consent. 2. Have received radioactive seed&#xD;
        implantation in the treatment area. 3. Suffer from uncontrolled disease which could&#xD;
        interfere treatment. 4. Suffered from another malignant tumor or multiple primary tumors at&#xD;
        the same time within 5 years (excluding fully treated basal cell or squamous cell skin&#xD;
        cancer, cervical cancer in situ, etc.). 5. The patient has surgical contraindications: such&#xD;
        as severe cardiopulmonary disease, coagulation dysfunction and so on. 6.The patients have&#xD;
        autoimmune diseases. 7. The patient is using immunosuppressive agents or systemic hormone&#xD;
        therapy to achieve the purpose of immunosuppression (dose&gt;10mg/day prednisone or other&#xD;
        curative hormones), and continues to use it within 2 weeks before the first administration;&#xD;
        8. Severe allergic reaction to other monoclonal antibodies; 9. Previously received PD-1&#xD;
        monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell&#xD;
        co-stimulation or checkpoint pathway) treatment; 10. Live vaccines have been inoculated&#xD;
        within 4 weeks before the first administration or during the study period; 11. The patient&#xD;
        has any situation that may hinder study compliance or the safety during the study&#xD;
        period.12. Existence of serious neurological or psychiatric diseases, such as dementia and&#xD;
        seizures; 13. Uncontrolled active infection. 14. Pregnant or breastfeeding women. 15. Those&#xD;
        who have no personal freedom and independent capacity for civil conduct;p. 16. There are&#xD;
        other situations that are not suitable for entry into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmeng Yu, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye&amp;ENT Hospital,Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaole Song, MD</last_name>
    <phone>15821388769</phone>
    <email>jxfxsxl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye&amp; ENT Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yan, MD</last_name>
      <phone>13761720601</phone>
      <email>yanl13@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoshen Wang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye &amp; ENT Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hongmeng Yu</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

